Newsletters
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
- All
- AMR Action Fund
- Can you help?
- CARB-X
- CDC
- FDA
- Government Action
- Jobs
- Meetings
- PK & PK-PD
- Push/Pull
- R&D Insight
- RFPs
- Something Different
- Summaries
- Wellcome Trust
- WHO
- Wonkish
Australia calls for Subscription (“Netflix”) models: Report and podcast
Dear All, With thanks to alert reader Liam Sharkey, a post-doc in Melbourne, for the heads-up on this topic, I am ...
Read More >
Global livestock resistome: Antibiotic resistance is widespread!
Dear All (and with thanks to Lance Price for co-authoring this deeply wonkish newsletter), Today we turn to the idea ...
Read More >
$ Impact of AMR in your country: Interactive web tool!
Dear All, The 27 Sep 2024 newsletter (“Without action, AMR costs go from $66b to $159b/yr by 2050”) reviewed a ...
Read More >
MHRA Seeks Chief Medical and Scientific Officer
Dear All, I have learned that UK’s MHRA (Medicines & Healthcare products Regulatory Agency) is recruiting for the role of Chief ...
Read More >
WHO: Draft TPPs for MDR bacterial infections
Dear All, Back in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A description of the ...
Read More >
Italy initiates its national pull Incentive!
Dear All (and with thanks to Damiano for taking the lead on this newsletter), We wrote previously in (i) the 7 ...
Read More >
BARDA RFP: Antibiotic for HABP/VABP or Bloodstream Infection
Dear All, BARDA have published an RFP (Request for Proposals) under which it would support clinical development and then stockpiling ...
Read More >
Vaccination to prevent AMR: Insights from Wellcome
Dear All (and with thanks to Vega Masignani for co-authoring this newsletter), Waaaay back in 2019 (pre-COVID … remember that?), ...
Read More >
The threat of mirror bacteria: Ongoing conversations
Dear All, I wrote in a 12 Dec 2024 newsletter (“Mirror Bacteria: An AMR threat of unprecedented magnitude”) about the ...
Read More >
Updated FDA Q&A on Antibacterials for Unmet Medical Need
Dear All, An updated version of FDA’s very helpful Q&A entitled “Antibacterial Therapies for Patients With an Unmet Medical Need ...
Read More >
UNGA 2024 action: Establishing an Independent Panel on Evidence for Action (IPEA)
Dear All, Referring back to the actions planned following the 2024 UNGA HLM on AMR (UN General Assembly High-Level Meeting ...
Read More >
Pull incentives in Europe: Next legislative steps
Dear All (Deeply wonkish alert! Settle in! Great stuff here!): For today, we have a deep dive into the ongoing ...
Read More >
Extending STEDI to diagnostics: STRIDES
Dear All (and with thanks to Betsy Trainor for co-authoring), The idea of the STEDI values of an antibiotic (its ...
Read More >
MHRA compilation of regulatory guidance on phage products
Dear All, Attention phage developers — the UK MHRA have compiled all their regulatory guidance for phage into one convenient ...
Read More >
D-Day: Churchill (1944) → WHO Pandemic Agreement and the Hamburg Statement (2025)
Dear All, D-Day and the momentous Normandy landings were 81 years ago today. In a marvelous new article on bbc.com (and ...
Read More >
FDA Listening Sessions for CEOs, CMOs, or heads of R&D
Dear All, Pushing this one out as a direct quote from the online materials posted yesterday by FDA. Looks interesting! All ...
Read More >
IDWeek 2025: Present your novel antimicrobial or diagnostic
Dear All, As in previous years (27 Mar 2024 newsletter), IDWeek 2025 will feature pipeline-focused sessions for both antimicrobials and ...
Read More >
Vaccine development: Polytheism vs. Monotheism
Dear All (and with a wonkish alert!), The idea of more (and better) vaccines to prevent (or even be part ...
Read More >
Impact of AMR on cancer therapy
Dear All (unapologetically wonkish … very important material!), Let’s set the scene today by considering two quotes: Prosaic: “The successful ...
Read More >
Evolving the idea of DTR (Difficult-to-Treat Resistance) to include antibiotic access
Dear All (wonkish alert … lots of details here … take your time and absorb it all!), I’ve written several ...
Read More >